Enalaprilat Injection

This product is the active form of enalapril and is a powerful angiotensin converting enzyme inhibitor. It is ineffective when taken orally and is only for intravenous injection. It can dilate peripheral blood vessels in patients with hypertension and lower blood pressure. After intravenous injection of this product in patients with congestive heart failure, coronary blood vessels dilate, mean arterial pressure decreases, pulmonary capillary wedge pressure decreases, myocardial oxygen consumption decreases, and cardiac index and stroke volume increase.

Phenylpropionic acid.

This product is for injection.

It is suitable for the treatment of patients with acute or hypertensive crisis who need rapid blood pressure reduction and patients with stable heart failure, especially for patients who are in a coma and cannot take oral medication for various reasons. This product does not reduce cerebral blood flow, so it is also suitable for patients who may be in danger of insufficient blood supply to the brain due to a drop in blood pressure.

For intravenous injection, patients with hypertension take 10-40 mg each time, and the effect is most obvious within about 30 minutes; when the dose exceeds 40 mg, the effect is no longer enhanced, but the duration is prolonged. It can also be used 1.25-5 mg, once every 6 hours. For patients with congestive heart failure, it is generally 2.5-5 mg each time, once a day. When the condition is controlled, it is generally switched to oral enalapril for continued treatment. Each 10 mg of this product is approximately equivalent to 20 mg of enalapril.

A small number of patients have adverse reactions such as hypotension or postural hypotension, dizziness, headache, nausea, abdominal pain, rash, weakness, angioedema, cough, increased blood urea nitrogen, and hyperlipidemia. Some patients also have decreased hemoglobin, decreased leukocytes, and increased transaminase.

Patients with severe renal impairment should use it with caution in a reduced dose. It is contraindicated in patients with hypotension.

1. When used with furosemide, it can enhance the antihypertensive effect of this product and prolong the duration of action. 2. When used with sympathetic blockers and ganglion blockers, caution should be exercised. 3. When used with certain beta-receptor blockers, it can enhance the antihypertensive effect of this product. 4. When used with potassium salts and potassium-containing drugs, this product can cause hyperkalemia.

Keep sealed.

1 ml: 1.25 mg (based on C18H24N2O5)

Changzhou Pharmaceutical Factory Co., Ltd.

• Founded in:

  2001-12-14

• Address:

  No. 518, Laodong East Road, Changzhou

• Tax NO.:

  91320400137158490L

• Registered Funds:

  108 million yuan

• Website:

  Log in to view

• Email:

  Log in to view